<DOC>
	<DOCNO>NCT02338232</DOCNO>
	<brief_summary>This single-center , open-label , prospective study telmisartan prevention acute GVHD approximately 60 subject undergoing allogeneic HCT treatment hematologic malignancy .</brief_summary>
	<brief_title>Pilot Study Telmisartan ( Micardis ) For Prevention Acute Graft v . Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>This single-center , open-label , prospective study telmisartan prevention acute GVHD approximately 60 subject undergoing allogeneic HCT treatment hematologic malignancy . Subjects receive 160 mg Micardis brand telmisartan daily , start 2 day prior HCT ( day -2 ) . Once patient discharge post-HCT , treatment continue Day +98 post-HCT total 101 day . After treatment discontinuation day +98 post-HCT , subject follow 6 month primary secondary endpoint .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Diagnosis : Acute myeloid lymphoid leukemia remission , Myelodysplastic syndrome , Chronic lymphoid leukemia , NonHodgkin lymphoma , Hodgkin lymphoma , Chronic myeloid leukemia chronic accelerate phase , Myeloproliferative disorder , Multiple myeloma Undergoing allogeneic HSC transplantation relate unrelated donor match least 7 8 HLAA , B , C , DR locus ( `` 8/8 '' `` 7/8 '' match ) Undergoing allogeneic HSC transplantation myeloablative TBI , busulfan , ( nonmyeloablative ) melphalanbased pretransplant conditioning regimen . Regimens transplantation include one follow agent , give conjunction fludarabine cyclophosphamide : Busulfan 130 mg/m2 iv daily x 2 ( reduce intensity ) 4 day TBI 150 cGy bid x8 dos ( 1200 Gy ) Melphalan 140 mg/m2 . ( Although melphalan myeloablative regimen , result clinically significant mucositis patient receive medication considerable interest analysis data . ) Male female patient age 18 year old Karnofsky performance status &gt; 70 % time initiation pretransplant condition Transplantationspecific comorbidity score &lt; 3 time initiation pretransplant conditioning Patients take antihypertensive medication ( include telmisartan ) eligible patient must discontinue treatment least 48 hour prior first dose study medication Capable give informed consent sign informed consent form Inability provide inform consent Subjects know heart failure , advance renal impairment require renal replacement therapy , liver failure although patient would likely eligible HCT . Subjects take ACE inhibitor , potassium supplement , spironolactone ( potassiumsparing diuretic ) discontinue use prior initiation study treatment OR require highpotassium diet Patient unable discontinue current hypertension medication medical reason two day prior start telmisartan Chronic symptomatic hypotension , volume depletion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>